
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
— Hippocrates

The landmark 5-year follow-up data from the DiRECT trial provides clear evidence regarding diabetes remission cost-effectiveness. Recent results show that an intensive weight management program significantly improves long-term health outcomes while reducing overall healthcare costs. Consequently, this intervention offers a sustainable solution for managing Type 2 Diabetes (T2DM) in primary care settings.
Over the five-year period, participants in the intervention arm achieved an average weight loss of 6.1 kg. Furthermore, approximately 10% of these individuals remained in remission from T2DM at the five-year mark. Notably, the total discounted healthcare cost savings per participant amounted to £2,091, excluding the initial intervention costs. Therefore, the program demonstrates both clinical efficacy and financial viability.
The researchers calculated an Incremental Cost-Effectiveness Ratio (ICER) of £13,541 per Quality-Adjusted Life-Year (QALY). This figure falls well below the standard willingness-to-pay thresholds used in many global healthcare systems. Moreover, the probability of the intervention being cost-effective reaches 98% at a £20,000 per QALY threshold. In contrast to standard care, this approach provides more life-years in remission and a better quality of life for patients.
Healthcare providers should consider total diet replacement and structured support as a primary strategy for early T2DM. This model reduces the medication burden, specifically for anti-hypertensive and anti-diabetic drugs. Additionally, the long-term reduction in primary and secondary care contacts offsets the initial costs of the formula diet and practitioner visits. Ultimately, prioritizing weight-mediated remission can transform the economic landscape of diabetes care.
The intervention uses the Counterweight-Plus program, which includes a low-energy formula diet (825–853 kcal/day) for 12–20 weeks, followed by food reintroduction and long-term weight maintenance support.
Yes, the DiRECT trial showed that 10% of participants remained in remission at 5 years, with those maintaining significant weight loss having the highest success rates.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Davies A et al. Cost-effectiveness of the diabetes remission clinical trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow-up. Diabet Med. 2026 Mar 29. doi: 10.1111/dme.70306. PMID: 41904649.
Lean MEJ, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12(4):233-246.
Arpan, Singh N, et al. Achieving Diabetes Remission: Current Guidelines and Emerging Pharmacotherapies in India. J Assoc Physicians India 2025;73(10):83-86.

The 5-year DiRECT trial results prove that intensive weight management for T2DM remission is highly cost-effective, saving £2,091 in healthcare costs per pa...
last month

A large-scale study reveals a 25% higher risk of CKD in night shift workers, largely driven by obesity and disrupted fatty acid metabolism....
Today

The SRS 2024 report highlights a decline in India's infant mortality rate to 24, though severe state-level disparities and neonatal care gaps persist....
Today

A survey of 105 specialists identifies cost and procedural time as key barriers to IVUS use in CLTI revascularization, highlighting the need for randomized ...
Today

Researchers find that FLNB and TTC26 regulate ciliary Hedgehog signaling to maintain intervertebral disc matrix and prevent adolescent idiopathic scoliosis....
Today

Stanford scientists cured Type 1 diabetes in mice by transplanting stem and islet cells under a gentle, low-radiation protocol to reset the immune system....
Today